University of Texas's MD Anderson Cancer Center: AACR - Combination Immunotherapy Treatment Effective Before Lung Cancer Surgery
April 12, 2022
April 12, 2022
HOUSTON, Texas, April 12 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 11, 2022:
* * *
Translational findings support combinations over single-agent therapy
* * *
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCL . . .
* * *
Translational findings support combinations over single-agent therapy
* * *
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCL . . .